

RECEIVED
CENTRAL FAX CENTER
DEC 10 2008

FAX TRANSMISSION

DATE: December 10, 2008

PTO IDENTIFIER: Application Number 09/423,037
Patent Number

Inventor: Heery et al.

MESSAGE TO: US Patent and Trademark Office

FAX NUMBER: (571) 273-8300

FROM: ROPES & GRAY LLP
David P. Halstead, J.D., Ph.D.

PHONE: (617) 951-7615

Attorney Dkt. #: ASZD-P01-228

PAGES (Including Cover Sheet): 11

CONTENTS: Amendment in Response to Final Office Action (9 pages)
Amendment Transmittal (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 951-7615 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

ROPES & GRAY LLP
One International Place, Boston, Massachusetts 02110
Telephone: (617) 951-7000 Facsimile: (617) 951-7050

RECEIVED
CENTRAL FAX CENTER
DEC 10 2008

AMENDMENT TRANSMITTAL LETTER				Docket No. ASZD-P01-228	
Application No. 09/423,037		Filing Date February 22, 2000		Examiner J. A. Dunston	
				Art Unit 1636	

Applicant(s): Heery et al.

Invention: INHIBITORS OF NUCLEAR PROTEIN/NUCLEAR RECEPTOR INTERACTION

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.
The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED						
	Claims Remaining After Amendment	Highest Number Previously Paid		Number Extra Claims Present	Rate	
Total Claims	35	- 56 =		0	x 52.00	0.00
Independent Claims	1	- 3 =		0	x 220.00	0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>						
Other fee (please specify):						
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:						0.00

☒ Large Entity ☐ Small Entity

☒ No additional fee is required for this amendment.

☐ Please charge Deposit Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.

☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.

☐ Payment by credit card. Form PTO-2038 is attached.

☒ The Director is hereby authorized to charge and credit Deposit Account No. 18-1945
as described below. A duplicate copy of this sheet is enclosed.

☒ Credit any overpayment.

☒ Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.

Dated: December 10, 2008

David P. Halstead, J.D., Ph.D.
Attorney/Agent Reg. No.: 44,735

ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110
(617) 951-7615

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: December 10, 2008 Signature: Pamela Harrison (Pamela A. Harrison)


RECEIVED
CENTRAL FAX CENTER
DEC 10 2008

003/011

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: December 10, 2008

Signature:


(Pamela Harrison)

Docket No.: ASZD-P01-228
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Heery et al.

Application No.: 09/423,037

Confirmation No.: 6259

Filed: February 22, 2000

Art Unit: 1636

For: INHIBITORS OF NUCLEAR
PROTEIN/NUCLEAR RECEPTOR
INTERACTION

Examiner: J. A. Dunston

AMENDMENT IN RESPONSE TO FINAL OFFICE ACTION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated October 16, 2008, please amend the above-identified U.S. patent application as follows.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.